| scholarly article | Q13442814 |
| P356 | DOI | 10.1126/SCIENCE.3299709 |
| P698 | PubMed publication ID | 3299709 |
| P50 | author | Stephen L. Hoffman | Q60231547 |
| P2093 | author name string | Chulay JD | |
| Hollingdale MR | |||
| Wirtz RA | |||
| Plowe CV | |||
| Beier JC | |||
| Oster CN | |||
| Mugambi M | |||
| Woollett GR | |||
| P433 | issue | 4815 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| antibody | Q79460 | ||
| malaria vaccine | Q6741353 | ||
| vaccine | Q134808 | ||
| malaria prevention | Q93598033 | ||
| P1104 | number of pages | 4 | |
| P304 | page(s) | 639-642 | |
| P577 | publication date | 1987-08-01 | |
| P1433 | published in | Science | Q192864 |
| P1476 | title | Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications | |
| P478 | volume | 237 |
| Q48002588 | 'Original antigenic sin', T cell memory, and malaria sporozoite immunity: an hypothesis for immune evasion |
| Q37147135 | 1 Antimalarial Activity of the 8-Aminoquinolines |
| Q33859633 | A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray |
| Q34520456 | A prospective study of the association between the human humoral immune response to Plasmodium falciparum blood stage antigen gp190 and control of malarial infections. |
| Q53700367 | A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. |
| Q44146077 | A rapid inhibition micro ELISA for detecting antibodies to Plasmodium falciparum sporozoites in human blood |
| Q46223301 | A theoretical framework for the immunoepidemiology of Plasmodium falciparum malaria. |
| Q24651173 | Acquired immunity to malaria |
| Q47879434 | Activity of human volunteer sera to candidate Plasmodium falciparum circumsporozoite protein vaccines in the inhibition of sporozoite invasion assay of human hepatoma cells and hepatocytes. |
| Q35084077 | Adoptive transfer of immunity to Theileria parva in the CD8+ fraction of responding efferent lymph |
| Q38993794 | Analysis of Plasmodium falciparum infections in a village community in Northern Nigeria: determination of msp2 genotypes and parasite-specific IgG responses |
| Q47859209 | Anti-circumsporozoite protein antibodies measure age related exposure to malaria in Kataragama, Sri Lanka |
| Q37800092 | Anti-sporozoite antibodies |
| Q92965786 | Antibodies against Plasmodium falciparum malaria at the molecular level |
| Q40484421 | Antibodies to the Circumsporozoite Protein and Protective Immunity to Malaria Sporozoites |
| Q36668494 | Antibody responses to Plasmodium falciparum and P. vivax sporozoites in areas with stable and unstable malaria |
| Q35946430 | Antigenic diversity and immune evasion by malaria parasites. |
| Q37278891 | Assessment of the relative success of sporozoite inoculations in individuals exposed to moderate seasonal transmission |
| Q40193241 | Characterization of antibodies to sporozoites in Plasmodium falciparum malaria and correlation with protection |
| Q41194352 | Circumsporozoite antibodies and falciparum malaria incidence in children living in a malaria endemic area |
| Q36366362 | Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity |
| Q41200913 | Comparative analysis of ELISAs employing repetitive peptides to detect antibodies to Plasmodium falciparum sporozoites |
| Q90300290 | Complement in malaria immunity and vaccines |
| Q30420219 | Controlling malaria: competition, seasonality and 'slingshotting' transgenic mosquitoes into natural populations |
| Q47896240 | Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate |
| Q38953222 | Cross-stage immunity for malaria vaccine development |
| Q37635135 | Decreased growth rate of P. falciparum blood stage parasitemia with age in a holoendemic population |
| Q37175173 | Differential antibody responses to Plasmodium falciparum and P. vivax circumsporozoite proteins in a human population |
| Q41200573 | ELISA method for detecting Plasmodium falciparum circumsporozoite antibody |
| Q36668566 | Evaluation of an in vitro assay aimed at measuring protective antibodies against sporozoites |
| Q36668533 | Evidence implicating MHC genes in the immunological nonresponsiveness to the plasmodium falciparum CS protein |
| Q47976889 | Experimental asexual blood stage malaria immunity |
| Q33617329 | Expression and immune recognition of the conserved MSP4 outer membrane protein of Anaplasma marginale |
| Q46662804 | Fine epitope specificity of antibodies to region II of the Plasmodium vivax circumsporozoite protein correlates with ability to bind recombinant protein and sporozoites |
| Q62738086 | Functional antibodies against sporozoites are associated with a longer time to qPCR-detected infection among schoolchildren in Burkina Faso |
| Q36674065 | Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex Class I-dependent interferon-gamma-producing CD8+ T cells |
| Q33798041 | Hepatitis C virus infection may lead to slower emergence of P. falciparum in blood |
| Q36726723 | High road, low road? Choices and challenges on the pathway to a malaria vaccine |
| Q52715900 | Human antibodies activate complement against Plasmodium falciparum sporozoites, and are associated with protection against malaria in children. |
| Q48028231 | Identification and characterization of the protective hepatocyte erythrocyte protein 17 kDa gene of Plasmodium yoelii, homolog of Plasmodium falciparum exported protein 1. |
| Q47904847 | IgM antibody responses to the circumsporozoite protein in naturally acquired falciparum malaria |
| Q43952848 | Immune responses to Plasmodium falciparum antigens during a malaria vaccine trial in Tanzanian children |
| Q37800091 | Immune responses to sporozoite antigens and their relationship to naturally acquired immunity to malaria |
| Q38689264 | Immunity to malaria in an era of declining malaria transmission |
| Q50041449 | Immunization of malaria pre-exposed volunteers with PfSPZ Vaccine elicits long-lived IgM invasion-inhibitory and complement-fixing antibodies |
| Q34601683 | Immunoglobulin G antibodies to merozoite surface antigens are associated with recovery from chloroquine-resistant Plasmodium falciparum in Gambian children |
| Q44172196 | Kinetics of expression of two major Plasmodium berghei antigens in the mosquito vector, Anopheles stephensi |
| Q37113126 | Linking environmental variability to village-scale malaria transmission using a simple immunity model |
| Q34028638 | Low doses of killed parasite in CpG elicit vigorous CD4+ T cell responses against blood-stage malaria in mice. |
| Q57954052 | Malaria diagnosis: memorandum from a WHO meeting |
| Q47854035 | Malaria. Getting into the liver |
| Q41739876 | Molecular basis for evasion of host immunity and pathogenesis in malaria |
| Q24798369 | Molecular dissection of the human antibody response to the structural repeat epitope of Plasmodium falciparum sporozoite from a protected donor |
| Q47864161 | Multiple antigen peptides for specific detection of antibodies to a malaria antigen in human sera |
| Q94950040 | OMIP-064: A 27-Color Flow Cytometry Panel to Detect and Characterize Human NK Cells and Other Innate Lymphoid Cell Subsets, MAIT Cells, and γδ T Cells |
| Q48021082 | Plasmodium berghei-specific T cells respond to non-processed sporozoites presented by B cells |
| Q37003064 | Plasmodium chabaudi malaria: protective immunization with surface membranes of infected erythrocytes. |
| Q34419934 | Plasmodium immunomics. |
| Q36644236 | Pre-erythrocytic malaria vaccines: identifying the targets |
| Q34521010 | Progress and challenges for malaria vaccines |
| Q35094826 | Protection of Malian children from clinical malaria is associated with recognition of multiple antigens |
| Q37241837 | Protective value of elevated levels of gamma interferon in serum against exoerythrocytic stages of Plasmodium falciparum |
| Q34264618 | Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuatedPlasmodium falciparumsporozoite vaccine |
| Q38665423 | Rationale for the development of an engineered sporozoite malaria vaccine |
| Q47863358 | Recognition of dominant T cell-stimulating epitopes from the circumsporozoite protein of Plasmodium falciparum and relationship to malaria morbidity in Gambian children |
| Q39075264 | Steps towards a malaria vaccine |
| Q33312392 | Sterile protection against malaria is independent of immune responses to the circumsporozoite protein |
| Q33747338 | The Antibody-Secreting Cell Response to Infection: Kinetics and Clinical Applications |
| Q36650703 | The circumsporozoite protein of Plasmodium: a mechanism of immune evasion by the malaria parasite? |
| Q40910243 | The development of a multivalent DNA vaccine for malaria |
| Q47640667 | The hope but challenge for developing a vaccine that might control malaria |
| Q37012062 | The immunological challenges of malaria vaccine development |
| Q33970972 | The immunology of malaria infection |
| Q52307983 | The maintenance of strain structure in populations of recombining infectious agents. |
| Q36668549 | The role of cytokines in malaria infection |
| Q28473729 | Transcriptional analysis of the pre-erythrocytic stages of the rodent malaria parasite, Plasmodium yoelii |
| Q36668498 | Use of non-human primate hepatocytes for in vitro study of the pre-erythrocytic stages of malaria parasites |
| Q36117148 | Vaccination against malaria |
| Q39296506 | Vaccines to Accelerate Malaria Elimination and Eventual Eradication |
| Q33587443 | Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model |
| Q37426820 | World Malaria Day 2009: what malaria knows about the immune system that immunologists still do not. |
Search more.